Jazz earns ex­pand­ed ap­proval for drug with con­tro­ver­sial his­to­ry, prompt­ing ex­pert push­back

Twen­ty-sev­en years ago, the FDA and the Na­tion­al Or­ga­ni­za­tion for Rare Dis­or­ders ap­proached ex­ec­u­tives of a small Min­neso­ta drug­mak­er and asked whether they could turn …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER